-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15

Benzinga·09/17/2026 12:17:59
Listen to the news
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.